FindTrial
Sign In

Efficacy and prognosis of HA380 perfusion combined with continuous venovenous hemofiltration in the treatment of sepsis

Efficacy and prognosis of HA380 perfusion combined with continuous venovenous hemofiltration in the treatment of sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082281
Enrollment
Unknown
Registered
2024-03-26
Start date
2021-06-05
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Observation group:HA380 perfusion combined with CVVH
Control group:CVVH only

Sponsors

The First Affiliated Hospital of Gannan Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Sepsis meets the diagnostic criteria of sepsis guidelines jointly issued by the American Society of Critical Care Medicine and the European Society of Critical Care Medicine. (2) Age=18 years, =75 years. (3) APACHE II score>8. (4) This study was approved by the hospital ethics committee, the informed consent of patients or their families.

Exclusion criteria

Exclusion criteria: (1) Blood purification contraindications. (2) Terminal state. (3) Pregnancy and lactation. (4) With autoimmune diseases, cerebrovascular diseases.

Design outcomes

Primary

MeasureTime frame
IL-6;TNF-a;Endotoxin;CRP;—

Secondary

MeasureTime frame
I-FABP;DAO;D-lactic acid;WBC count;PCT;Blood lactic acid;Serum creatinine;Blood urea nitrogen;Bilirubin;Intra-abdominal pressure;One-day body temperature peak;SOFA score;—

Countries

China

Contacts

Public ContactJie Wang

The First Affiliated Hospital of Gannan Medical University

wangjie0797@163.com+86 139 7971 8207

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026